Improving opioid treatment and HIV prevention in prisons
PRIDE III Prison Interventions and HIV Prevention Collaboration
This study is trying to find out what makes it hard to provide opioid treatment in prisons in Tajikistan, Kyrgyzstan, Moldova, and Georgia, so that they can improve care for people with addiction and help prevent HIV.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Yale University Academic / other |
| Locations | 5 sites (New Haven, Connecticut and 4 other locations) |
| Trial ID | NCT06962033 on ClinicalTrials.gov |
What this trial studies
This project aims to identify barriers to the implementation of Opioid Agonist Therapy (OAT) within the justice systems of Tajikistan, Kyrgyzstan, Moldova, and Georgia. It involves creating NIATx learning collaboratives with prison OAT providers and probation officers to enhance the scale-up of OAT. Data will be collected from national OAT databases and through surveys administered to prison narcologists and probation officers every six months. Additionally, ethnographic methods will be employed to observe and interview probation clients and staff.
Who should consider this trial
Good fit: Ideal candidates include probation officers and individuals currently on probation who have a history of opioid injection.
Not a fit: Patients not currently involved in the justice system or those without a history of opioid use may not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could significantly improve access to opioid treatment and reduce HIV transmission among incarcerated populations.
How similar studies have performed: Previous studies have shown promise in implementing OAT in similar settings, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Aim 1: 1. Quantitative surveys for prison OAT providers * Being 18 years or older * Being currently assigned and working as a probation OAT provider for a probation site 2. ECHO procedures Aim 2: 1. Quantitative surveys for people in probation * Being 18 years or older * Screen yes to opioid injection on the online screener questionnaire * Currently in probation 2. Quantitative surveys for probation and prison officers * Being 18 years or older * Being currently assigned and working as a probation or prison officer at a probation site 3. Focus Groups (People in probation) * Being 18 years or older * Screen yes to opioid injection criteria on the online screener * Currently in probation 4. Focus Groups (Probation and prison officers) * Being 18 years or older * Being currently assigned and working as a probation or prison officer at a probation * Has more than 3 months of field experience * Works at a probation site within 25 kilometers of an OAT site Exclusion Criteria: \-
Where this trial is running
New Haven, Connecticut and 4 other locations
- Yale University — New Haven, Connecticut, United States (Not_yet_recruiting)
- Alternative Georgia — Tbilisi, Georgia (Recruiting)
- AIDS Foundation East-West (AFEW) — Bishkek, Kyrgyzstan (Recruiting)
- Ngo Afi — Chisinau, Moldova (Recruiting)
- Institute for International Health and Education (IIHE) — Dushanbe, Tajikistan (Recruiting)
Study contacts
- Principal investigator: Frederick L Altice, MD — Yale University
- Study coordinator: David Oliveros, MPH
- Email: david.oliveros@yale.edu
- Phone: 202-805-8118
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.